Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
Nature Genetics2017Vol. 49(3), pp. 444–450
Citations Over TimeTop 10% of 2017 papers
Luca Magnani, Gianmaria Frigè, Raffaella Maria Gadaleta, Giacomo Corleone, Sonia Fabris, Hermannus Kempe, Pernette J. Verschure, Iros Barozzi, Valentina Vircillo, Sung-Pil Hong, Ylenia Perone, Massimo Saini, Andreas Trumpp, Giuseppe Viale, Antonino Neri, Simak Ali, Marco Colleoni, Giancarlo Pruneri, Saverio Minucci
Related Papers
- → Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole(2004)39 cited
- → Aromatase inhibitor (anastrozole) affects growth of endometrioma cells in culture(2015)10 cited
- → Anastrozole – A New Generation in Aromatase Inhibition: Clinical Pharmacology(1997)22 cited
- → 14 SUBGROUPS OF PATIENTS TREATED WITH AN AROMATASE INHIBITOR (ANASTROZOLE) DELIVERED SUBCUTANEOUSLY IN COMBINATION WITH TESTOSTERONE(2012)4 cited
- The effects of an aromatase inhibitor (anastrozole) or sulfatase inhibitor (STX64) on androgen concentrations in postmenopausal women with breast cancer.(2006)